Aurinia Pharmaceuticals (FRA:IKAP) Short Interest


FRA:IKAP Aurinia Pharmaceuticals Inc FRA:IKAP
77 GF Score
Price €16.40
GF Value €13.05
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:IKAP vs OCUL, NTLA, TYRA: Short Interest Comparison

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aurinia Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Short Interest falls into.


FRA:IKAP
77GF Score
Aurinia Pharmaceuticals Inc FRA:IKAP
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aurinia Pharmaceuticals (FRA:IKAP) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of €16.40 is trading 25.6% above its estimated GF Value™ of €13.05. GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for FRA:IKAP:

  • Short Interest:
  • GF Value™: €13.05 vs. price of €16.40 (25.6% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the FRA:IKAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurinia Pharmaceuticals Business Description

Other Exchanges AUPH:USAIKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
77GF Score

Get the complete analysis for FRA:IKAP

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.40
Price
€13.05
GF Value